Targeting the β₂ -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.

ABSTRACT: While multi-drug combinations and continuous treatment have become standard for multiple myeloma, the disease remains incurable. Repurposing drugs that are currently used for other indications could provide a novel approach to improve the therapeutic efficacy of standard multiple myeloma treatments. Here, we assessed the anti-tumor effects of cardiac drugs called β-blockers as a single agent and in combination with commonly used anti-myeloma therapies. Expression of the β₂ -adrenergic receptor correlated with poor survival outcomes in patients with multiple myeloma. Targeting the β₂ -adrenergic receptor (β₂ AR) using either selective or non-selective β-blockers reduced multiple myeloma cell viability, and induced apoptosis and autophagy. Blockade of the β

SUBMITTER: Satilmis H 

PROVIDER: S-EPMC10953387 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature